These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 555868)
1. Enhanced efflux of actinomycin D, vincristine, and vinblastine in adriamycin-resistant subline of P388 leukemia. Inaba M; Sakurai Y Cancer Lett; 1979 Dec; 8(2):111-5. PubMed ID: 555868 [TBL] [Abstract][Full Text] [Related]
2. Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin. Tsuruo T; Iida H; Yamashiro M; Tsukagoshi S; Sakurai Y Biochem Pharmacol; 1982 Oct; 31(19):3138-40. PubMed ID: 7150340 [TBL] [Abstract][Full Text] [Related]
3. A simple fluorometric method to discriminate adriamycin-resistant subline from adriamycin-sensitive parental P388 murine leukemia cell line. Dekker K; Kojima N; Yamamoto S; Tatsumi K; Mino M; Yagi K Biochem Int; 1987 Jun; 14(6):997-1001. PubMed ID: 3453100 [TBL] [Abstract][Full Text] [Related]
4. Active efflux common to vincristine and daunorubicin in vincristine-resistant P388 leukemia. Inaba M; Fujikura R; Sakurai Y Biochem Pharmacol; 1981 Jul; 30(13):1863-5. PubMed ID: 7271878 [No Abstract] [Full Text] [Related]
5. Kinetic analysis of active efflux of vincristine from multidrug-resistant P388 leukemia cells. Inaba M; Watanabe T; Sugiyama Y Jpn J Cancer Res; 1987 Apr; 78(4):397-404. PubMed ID: 3108219 [TBL] [Abstract][Full Text] [Related]
6. Restored in vitro sensitivity of adriamycin- and vincristine-resistant P388 leukemia with reserpine. Inaba M; Fujikura R; Tsukagoshi S; Sakurai Y Biochem Pharmacol; 1981 Aug; 30(15):2191-4. PubMed ID: 7295334 [No Abstract] [Full Text] [Related]
7. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y Cancer Res; 1982 Nov; 42(11):4730-3. PubMed ID: 7127307 [TBL] [Abstract][Full Text] [Related]
8. Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukemia. Inaba M; Johnson RK Cancer Res; 1977 Dec; 37(12):4629-34. PubMed ID: 922743 [TBL] [Abstract][Full Text] [Related]
9. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine. Ganapathi R; Grabowski D; Schmidt H Biochem Pharmacol; 1986 Feb; 35(4):673-8. PubMed ID: 3947398 [TBL] [Abstract][Full Text] [Related]
10. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells. Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108 [TBL] [Abstract][Full Text] [Related]
11. Mechanism of natural resistance to vincristine in rat ascites hepatoma AH66. Inaba M; Takayama K; Sakurai Y Gan; 1981 Aug; 72(4):562-8. PubMed ID: 7308668 [TBL] [Abstract][Full Text] [Related]
12. Non-antitumor vinca alkaloids reverse multidrug resistance in P388 leukemia cells in vitro. Inaba M; Nagashima K Jpn J Cancer Res; 1986 Feb; 77(2):197-204. PubMed ID: 3082832 [TBL] [Abstract][Full Text] [Related]
13. Resistance and cross-resistance of cultured leukemia P388 cells to vincristine, adriamycin, adriamycin analogs, and actinomycin D. Wilkoff LJ; Dulmadge EA J Natl Cancer Inst; 1978 Dec; 61(6):1521-4. PubMed ID: 281559 [TBL] [Abstract][Full Text] [Related]
14. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Tsuruo T; Iida H; Kitatani Y; Yokota K; Tsukagoshi S; Sakurai Y Cancer Res; 1984 Oct; 44(10):4303-7. PubMed ID: 6467192 [TBL] [Abstract][Full Text] [Related]
15. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Goldenberg GJ; Wang H; Blair GW Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020 [TBL] [Abstract][Full Text] [Related]
16. Effects of ruthenium red on accumulation and cytotoxicity of m-AMSA, vinblastine and daunorubicin in leukemia cells. Wilberding C; Kessel D Biochem Pharmacol; 1984 Aug; 33(16):2559-62. PubMed ID: 6205658 [TBL] [Abstract][Full Text] [Related]
17. Enhancement of doxorubicin and vinblastine sensitivity in anthracycline-resistant P388 cells. Ramu A; Shan TC; Glaubiger D Cancer Treat Rep; 1983 Oct; 67(10):895-9. PubMed ID: 6354437 [TBL] [Abstract][Full Text] [Related]
18. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine. Inaba M; Maruyama E Cancer Res; 1988 Apr; 48(8):2064-7. PubMed ID: 3349478 [TBL] [Abstract][Full Text] [Related]
19. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone. Gutierrez PL; Wilder PJ; Biswal N Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972 [TBL] [Abstract][Full Text] [Related]
20. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Tsuruo T; Iida H; Nojiri M; Tsukagoshi S; Sakurai Y Cancer Res; 1983 Jun; 43(6):2905-10. PubMed ID: 6850602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]